Clinical Trials Browser

Phase 1/2 × INDUSTRY × 64Cu-SARTATE × Clear all

NCT04023331 2025-09-16

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Phase 1/2 Terminated

Neuroblastoma

NCT03936426 2020-04-20

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Phase 1/2 Completed

Meningioma